ATAC trial update

Lancet. 2005 Apr;365(9466):1225; author reply 1225-6. doi: 10.1016/S0140-6736(05)74802-9.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Anastrozole
  • Androstadienes / adverse effects
  • Androstadienes / therapeutic use
  • Antineoplastic Agents, Hormonal / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Aromatase Inhibitors / adverse effects
  • Aromatase Inhibitors / therapeutic use
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / mortality
  • Female
  • Humans
  • Myocardial Infarction / chemically induced
  • Nitriles / administration & dosage
  • Nitriles / adverse effects
  • Survival Rate
  • Tamoxifen / administration & dosage
  • Triazoles / administration & dosage
  • Triazoles / adverse effects

Substances

  • Androstadienes
  • Antineoplastic Agents, Hormonal
  • Aromatase Inhibitors
  • Nitriles
  • Triazoles
  • Tamoxifen
  • Anastrozole
  • exemestane